Oxidative Metabolism Genes in Ovarian Neoplasms

Abstract

BACKGROUND: Reactive oxygen species play important and ambiguous role in carcinogenesis, and local oxidative metabolism may differ significantly from systemic metabolism and determine the processes occurring in tumor tissues.

AIM: This study aimed to examine the expressions of key oxidative metabolism genes, particularly CYB5R, POR, NOX4, SOD1, NF-κB, and NRF2, in ovarian neoplasm tissues, and determine cytochrome b5 reductase and cytochrome P450 reductase activity, blood neutrophil activity, and antioxidant indices in the blood plasma and peritoneal fluid.

MATERIALS AND METHODS: The study included two groups of patients: a study group (n = 10) with ovarian adenocarcinoma and a comparison group (n = 6) with benign ovarian neoplasms. The expressions of CYB5R1, CYB5R2/R4, CYB5R3, POR, BIRC3, NOX4, NRF2, NF-κB, SOD1, HMOX1, and BCL2 genes, cytochrome b5 reductase, and cytochrome P450 reductase activity, oxidative activity of blood neutrophils, and antioxidant potential of plasma and peritoneal fluid were evaluated in these two groups of women.

RESULTS: The expression levels of CYB5R3 and BCL2 were significantly lower in adenocarcinoma tissues. The activities of cytochrome b5 reductase and cytochrome P450 reductase increased in the group with adenocarcinoma. On average, the activity of blood neutrophils corresponded to the reference values. For blood plasma, the antioxidant capacity were not different, whereas the antioxidant capacity in the peritoneal fluid increased approximately twofold in ovarian cancer.

CONCLUSIONS: Significantly increased cytochrome b5 reductase activity in adenocarcinoma tissues may be a response to intracellular oxidative stress, whereas CYB5R3 gene expression may be reduced by a negative feedback mechanism. The activities of cytochrome P450 reductase and its gene change to a lesser extent in the presence of ovarian adenocarcinoma. The oxidative balance in the blood and peritoneal fluid correlated with the tissue expressions of NF-κB and NRF2.

Keywords

cytochrome b5 reductase / cytochrome P450 reductase / NRF2 / NF-κB / blood plasma / antioxidant capacity / neutrophil activity / ovarian cancer

References

[1] Liu WJ, Huang YX,Wang W, et al. NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells. Cells. 2021;10(7):1647. doi: 10.3390/cells10071647

[2] Liu W.J., Huang Y.X.,Wang W., et al. NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells // Cells. 2021. Vol. 10, N. 7. P. 1647.doi: 10.3390/cells10071647

[3] Ding DN, Xie LZ, Shen Y, et al. Insights into the Role of Oxidative Stress in Ovarian Cancer. Oxid Med Cell Longev. 2021;2021:8388258. doi: 10.1155/2021/8388258

[4] Ding D.N., Xie L.Z., Shen Y., et al. Insights into the Role of Oxidative Stress in Ovarian Cancer // Oxid Med Cell Longev. 2021. Vol. 2021. P. 8388258. doi: 10.1155/2021/8388258

[5] Strycharz-Dudziak M, Foltyn S, Dworzanski J, et al. Glutathione Peroxidase (GPx) and Superoxide Dismutase (SOD) in Oropharyngeal Cancer Associated with EBV and HPV Coinfection. Viruses. 2020;12(9):1008. doi: 10.3390/v12091008

[6] Strycharz-Dudziak M., Foltyn S., Dworzanski J., et al. Glutathione Peroxidase (GPx) and Superoxide Dismutase (SOD) in Oropharyngeal Cancer Associated with EBV and HPV Coinfection // Viruses. 2020. Vol. 12, N. 9. P. 1008. doi: 10.3390/v12091008

[7] Singh N, Baby D, Rajguru JP, et al. Inflammation and cancer. Ann Afr Med. 2019;18(3):121–126. doi: 10.4103/aam.aam_56_18

[8] Singh N., Baby D., Rajguru J.P., et al. Inflammation and cancer // Ann Afr Med. 2019. Vol. 18, N. 3. P. 121–126. doi: 10.4103/aam.aam_56_18

[9] Sprooten J, Vankerckhoven A, Vanmeerbeek I, et al. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. J Immunother Cancer. 2021;9(11):e003609. doi: 10.1136/jitc-2021-003609

[10] Sprooten J., Vankerckhoven A., Vanmeerbeek I., et al. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer // J Immunother Cancer. 2021. Vol. 9, N. 11. P. e003609. doi: 10.1136/jitc-2021-003609

[11] Elahian F, Sepehrizadeh Z, Moghim B, Mirzaei SA. Human cytochrome b5 reductase: structure, function, and potential applications. Crit Rev Biotechnol. 2014;34(2):134–143.doi: 10.3109/07388551.2012.732031

[12] Elahian F., Sepehrizadeh Z., Moghim B., Mirzaei S.A. Human cytochrome b5 reductase: structure, function, and potential applications // Crit Rev Biotechnol. 2014. Vol. 34, N. 2. P. 134–143.ьdoi: 10.3109/07388551.2012.732031

[13] Lund RR, Leth-Larsen R, Caterino TD, et al. NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer. Mol Cell Proteomics. 2015;14(11):2988–2999. doi: 10.1074/mcp.M115.050385

[14] Lund R.R., Leth-Larsen R., Caterino T.D., et al. NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer // Mol Cell Proteomics. 2015. Vol. 14, N. 11. P. 2988–2999.ьdoi: 10.1074/mcp.M115.050385

[15] Wisniewska A, Jagiello K, Mazerska Z. NADPH-cytochrome P450 reductase, not only the partner of cytochrome P450. Postepy Biochem. 2009;55(3):272–278.

[16] Wisniewska A., Jagiello K., Mazerska Z. NADPH-cytochrome P450 reductase, not only the partner of cytochrome P450 // Postepy Biochem. 2009. Vol. 55, N. 3. P. 272–278.

[17] Proskurnina EV, Fedorova MV, Sozarukova MM, et al. Microsomal reductase activity in patients with thyroid neoplasms. Endocrine. 2021;72(3):735–743. doi: 10.1007/s12020-020-02513-z

[18] Proskurnina E.V., Fedorova M.V., Sozarukova M.M., et al. Microsomal reductase activity in patients with thyroid neoplasms // Endocrine. 2021. Vol. 72, N. 3. P. 735–743,doi: 10.1007/s12020-020-02513-z

[19] Saunders MP, Patterson AV, Chinje EC, Harris AL, Stratford IJ. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line. Br J Cancer. 2000;82(3):651–656. doi: 10.1054/bjoc.1999.0977

[20] Saunders M.P., Patterson A.V., Chinje E.C., Harris A.L., Stratford I.J. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line // Br J Cancer. 2000. Vol. 82, N. 3. P. 651–656. doi: 10.1054/bjoc.1999.0977

[21] Eliopoulos AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene. 1995;11(7):1217–1228.

[22] Eliopoulos A.G., Kerr D.J., Herod J., et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2 // Oncogene. 1995. Vol. 11, N. 7. P. 1217–1228.

[23] Marx D, Binder C, Meden H, et al. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer. Anticancer Res. 1997;17(3C):2233–2240.

[24] Marx D., Binder C., Meden H., et al. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer // Anticancer Res. 1997. Vol. 17, N. 3C. P. 2233–2240.

[25] Mano Y, Kikuchi Y, Yamamoto K, et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. Eur J Cancer. 1999;35(8):1214–1219.doi: 10.1016/s0959-8049(99)00124-0

[26] Mano Y., Kikuchi Y., Yamamoto K., et al. Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer // Eur J Cancer. 1999. Vol. 35, N. 8. P. 1214–1219.doi: 10.1016/s0959-8049(99)00124-0

[27] Liang M, Zhao J. Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis. Eur Rev Med Pharmacol Sci. 2018;22(16):5134–5139. doi: 10.26355/eurrev_201808_15708

[28] Liang M., Zhao J. Protein expressions of AIB1, p53 and Bcl-2 in epithelial ovarian cancer and their correlations with the clinical pathological features and prognosis // Eur Rev Med Pharmacol Sci. 2018. Vol. 22, N. 16. P. 5134–5139. doi: 10.26355/eurrev_201808_15708

[29] Baekelandt M, Kristensen GB, Nesland JM, Trope CG, Holm R. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol. 1999;17(7):2061.doi: 10.1200/JCO.1999.17.7.2061

[30] Baekelandt M., Kristensen G.B., Nesland J.M., Trope C.G., Holm R. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer // J Clin Oncol. 1999. Vol. 17, N. 7. P. 2061. doi: 10.1200/JCO.1999.17.7.2061

[31] Chaudhry P, Srinivasan R, Patel FD. Differential expression of Fas family members and Bcl-2 family members in benign versus malignant epithelial ovarian cancer (EOC) in North Indian population. Mol Cell Biochem. 2012;368(1–2):119–126.doi: 10.1007/s11010-012-1350-7

[32] Chaudhry P., Srinivasan R., Patel F.D. Differential expression of Fas family members and Bcl-2 family members in benign versus malignant epithelial ovarian cancer (EOC) in North Indian population // Mol Cell Biochem. 2012. Vol. 368, N. 1–2. P. 119–126.doi: 10.1007/s11010-012-1350-7

[33] Chen C, You F, Wu F, et al. Antiangiogenesis Efficacy of Ethanol Extract from Amomum tsaoko in Ovarian Cancer through Inducing ER Stress to Suppress p-STAT3/NF-kB/IL-6 and VEGF Loop. Evid Based Complement Alternat Med. 2020;2020:2390125.doi: 10.1155/2020/2390125

[34] Chen C., You F., Wu F., et al. Antiangiogenesis Efficacy of Ethanol Extract from Amomum tsaoko in Ovarian Cancer through Inducing ER Stress to Suppress p-STAT3/NF-kB/IL-6 and VEGF Loop // Evid Based Complement Alternat Med. 2020. Vol. 2020. P. 2390125.doi: 10.1155/2020/2390125

[35] Chen G, Zhu L, Yang Y, et al. Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis. Technol Cancer Res Treat. 2018;17:1533033818791500.doi: 10.1177/1533033818791500

[36] Chen G., Zhu L., Yang Y., et al. Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis // Technol Cancer Res Treat. 2018. Vol. 17. P. 1533033818791500.doi: 10.1177/1533033818791500

[37] Lichtenstein A, Seelig M, Berek J, Zighelboim J. Human neutrophil-mediated lysis of ovarian cancer cells. Blood. 1989;74(2): 805–809.

[38] Lichtenstein A., Seelig M., Berek J., Zighelboim J. Human neutrophil-mediated lysis of ovarian cancer cells // Blood. 1989. Vol. 74, N. 2. P. 805–809.

[39] Klink M, Jastrzembska K, Nowak M, et al. Ovarian cancer cells modulate human blood neutrophils response to activation in vitro. Scand J Immunol. 2008;68(3):328–336.doi: 10.1111/j.1365-3083.2008.02139.x

[40] Klink M., Jastrzembska K., Nowak M., et al. Ovarian cancer cells modulate human blood neutrophils response to activation in vitro // Scand J Immunol. 2008. Vol. 68, N. 3. P. 328–336.doi: 10.1111/j.1365-3083.2008.02139.x

[41] Tobon-Velasco JC, Cuevas E, Torres-Ramos MA. Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress. CNS Neurol Disord Drug Targets. 2014;13(9):1615–1626.doi: 10.2174/1871527313666140806144831

[42] Tobon-Velasco J.C., Cuevas E., Torres-Ramos M.A. Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress // CNS Neurol Disord Drug Targets. 2014. Vol. 13, N. 9. P. 1615–1626. doi: 10.2174/1871527313666140806144831

[43] Van der Wijst MGP, Brown R, Rots MG. Nrf2, the master redox switch: the Achilles’ heel of ovarian cancer? Biochim Biophys Acta. 2014;1846(2):494–509. doi: 10.1016/j.bbcan.2014.09.004

[44] Van der Wijst M.G.P., Brown R., Rots M.G. Nrf2, the master redox switch: the Achilles’ heel of ovarian cancer? // Biochim Biophys Acta. 2014. Vol. 1846, N. 2. P. 494–509.doi: 10.1016/j.bbcan.2014.09.004

[45] Cho HY, Kim K, Kim YB, Kim H, No JH. Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival. Int J Gynecol Cancer. 2017;27(3):412–419. doi: 10.1097/IGC.0000000000000908

[46] Cho H.Y., Kim K., Kim Y.B., Kim H., No J.H. Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival // Int J Gynecol Cancer. 2017. Vol. 27, N. 3. P. 412–419. doi: 10.1097/IGC.0000000000000908

[47] Huang TT, Hao DL, Wu BN, Mao LL, Zhang J. Uric acid demonstrates neuroprotective effect on Parkinson’s disease mice through Nrf2-ARE signaling pathway. Biochem Biophys Res Commun. 2017;493(4):1443–1449. doi: 10.1016/j.bbrc.2017.10.004

[48] Huang T.T., Hao D.L., Wu B.N., Mao L.L., Zhang J. Uric acid demonstrates neuroprotective effect on Parkinson’s disease mice through Nrf2-ARE signaling pathway // Biochem Biophys Res Commun. 2017. Vol. 493, N. 4. P. 1443–1449. doi: 10.1016/j.bbrc.2017.10.004

[49] Lin Y, Xie Y, Hao Z, et al. Protective Effect of Uric Acid on ox-LDL-Induced HUVECs Injury via Keap1-Nrf2-ARE Pathway. J Immunol Res. 2021;2021:5151168. doi: 10.1155/2021/5151168

[50] Lin Y., Xie Y., Hao Z., et al. Protective Effect of Uric Acid on ox-LDL-Induced HUVECs Injury via Keap1-Nrf2-ARE Pathway // J Immunol Res. 2021. Vol. 2021. P. 5151168.doi: 10.1155/2021/5151168

[51] Jiang Z, Fletcher NM, Ali-Fehmi R, et al. Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells. Gynecol Oncol. 2011;122(2):418–423. doi: 10.1016/j.ygyno.2011.04.051

[52] Jiang Z., Fletcher N.M., Ali-Fehmi R., et al. Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells // Gynecol Oncol. 2011. Vol. 122, N. 2. P. 418–423.doi: 10.1016/j.ygyno.2011.04.051

[53] Ghazy AA, El-Etreby NM, Rashad R, Moussa N. Role of Oxidative Stress in Prognosis of Ovarian Cancer. Egypt J Immunol. 2020;27(2):31–38.

[54] Ghazy A.A., El-Etreby N.M., Rashad R., Moussa N. Role of Oxidative Stress in Prognosis of Ovarian Cancer // Egypt J Immunol. 2020. Vol. 27, N. 2. P. 31–38.

[55] Senthil K, Aranganathan S, Nalini N. Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin Chim Acta. 2004;339(1–2):27–32. doi: 10.1016/j.cccn.2003.08.017

[56] Senthil K., Aranganathan S., Nalini N. Evidence of oxidative stress in the circulation of ovarian cancer patients // Clin Chim Acta. 2004. Vol. 339, N. 1–2. P. 27–32. doi: 10.1016/j.cccn.2003.08.017

[57] Hecht JL, Janikova M, Choudhury R, et al. Labile Heme and Heme Oxygenase-1 Maintain Tumor-Permissive Niche for Endometriosis-Associated Ovarian Cancer. Cancers (Basel). 2022;14(9):2242. doi: 10.3390/cancers14092242

[58] Hecht J.L., Janikova M., Choudhury R., et al. Labile Heme and Heme Oxygenase-1 Maintain Tumor-Permissive Niche for Endometriosis-Associated Ovarian Cancer // Cancers (Basel). 2022. Vol. 14, N. 9. P. 2242. doi: 10.3390/cancers14092242

[59] Jing T, Guo Y, Wei Y. Carboxymethylated pachyman induces ferroptosis in ovarian cancer by suppressing NRF1/HO-1 signaling. Oncol Lett. 2022;23(5):161. doi: 10.3892/ol.2022.13281.

[60] Jing T., Guo Y., Wei Y. Carboxymethylated pachyman induces ferroptosis in ovarian cancer by suppressing NRF1/HO-1 signaling // Oncol Lett. 2022. Vol. 23, N. 5. P. 161. doi: 10.3892/ol.2022.13281.

RIGHTS & PERMISSIONS

Eco-Vector